A double-blind, placebo-controlled, randomized, multi-centre, phase III study of MLC901 (NeuroAiDTMII) for the treatment of cognitive impairment after mild traumatic brain injury
PLOS One · 2025
DOI: 10.1371/journal.pone.0310229 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS One, 2025. Verfasst von Pavel I Pilipenko und 13 weiteren Autor:innen. Beteiligte Einrichtung: Novosibirsk State Medical University, Novosibirsk, Russia. Hauptthemen laut MEDLINE: Cognitive Dysfunction, Brain Concussion. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Moleac Pte Ltd.
Abstract (Originalsprache)
Introduction
About half of the world population will suffer from a traumatic brain injury (TBI) during their lifetime, of which about 90% of cases are mild TBI. Although up to 40% of adults with mild TBI experience persistent functional deficits, there is no proven-effective treatment to facilitate recovery after it. Methods and analysis This randomized placebo-controlled multi-centre study was aimed to examine the efficacy of herbal supplement MLC901 on complex attention following mild TBI at 6 months post-randomisation, as a primary outcome measured by CNS Vital signs (CNS-VS). Adults aged 18–65 years, who were 1–12-months post-mild TBI and experienced cognitive impairment, were randomly assigned to receive either MLC901 two capsules (0.4g/capsule) or placebo three times a day for 6 months using centralized stratified permuted block randomization. Secondary outcomes: Rivermead Post-Concussion Symptoms Questionnaire (RPQ; neurobehavioral sequelae); Health Related Quality of Life (QOLIBRI); Hospital Anxiety and Depression Scale (HADS); and safety. Mixed effects models of repeated measures with intention to treat analysis were employed. A Least Square Mean Difference (LSMD) from baseline to 3-, 6-, and 9-month follow-up was calculated with 95% confidence intervals (CI).
Results
In the analysis, 182 participants (47.8% females) were included. Multivariable mixed effects model analysis did not reveal significant improvements in complex attention (LSMD = −1.18 [95% CI −5.40; 3.03; p = 0.58]) and other cognitive domains at 6 months in the MLC901 group compared to the Placebo group. There were significant improvements in RPQ, QOLIBRI, anxiety and depression in the MLC901 group compared to the Placebo group at 6 and 9 months (LSMD −4.36 [−6.46; −2.26] and −4.07 [−6.22; −1.92], 4.84 [1.58; 8.10] and 3.74 [0.44; 7.03], −1.50 [−2.29; −0.71 and −0.96 [−1.84; −0.08], −1.14 [−1.92; −0.35] and −1.14 [−1.94; −0.34]), respectively. MLC901 tested was proven safe.
Conclusions
Although the 6-month treatment with MLC901 did not result in a statistically significant difference with placebo for CNS-VS measurement of cognitive domains in individuals with mild TBI, the study showed a clinically and statistically significant improvement in all clinical scales assessed by the investigators.
Trial registration
ClinicalTrials.gov identifier NCT04861688 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Novosibirsk State Medical University, Novosibirsk, Russia.
- Municipal Polyclinic № 106 of St. Petersburg, St. Petersburg, Russia.
- X7 Research, St. Petersburg, Russia.
- Nizhny Novgorod Regional Clinical Hospital named after N.A. Semashko, Nizhny Novgorod, Russia.
- Ivanovo Regional Clinical Hospital, Ivanovo, Russia.
- Scientific Research Center Eco Safety LLC, St. Petersburg, Russia.
ORCID-Profile: Anna A Ivanova, Alexey Y Khrulev, Valery L Feigin
Förderung
- Moleac Pte Ltd
Zitieren
APA
Pilipenko, P. I., Ivanova, A. A., Kotsiubinskaya, Y. V., Grigoryeva, V. N., Khrulev, A. Y., Skorokhodov, A. V., Gavrik, M. M., Mkrtchan, N. N., Majdan, M., Valkovic, P., Rabarova, D., Barker-Collo, S., Jones, K., & Feigin, V. L. (2025). A double-blind, placebo-controlled, randomized, multi-centre, phase III study of MLC901 (NeuroAiDTMII) for the treatment of cognitive impairment after mild traumatic brain injury. PLOS One. https://doi.org/10.1371/journal.pone.0310229
Vancouver
Pilipenko PI, Ivanova AA, Kotsiubinskaya YV, Grigoryeva VN, Khrulev AY, Skorokhodov AV, et al. A double-blind, placebo-controlled, randomized, multi-centre, phase III study of MLC901 (NeuroAiDTMII) for the treatment of cognitive impairment after mild traumatic brain injury. PLOS One. 2025. doi:10.1371/journal.pone.0310229
BibTeX
@article{Pilipenko2025,
author = {Pilipenko, Pavel I and Ivanova, Anna A and Kotsiubinskaya, Yulia V and Grigoryeva, Vera N and Khrulev, Alexey Y and Skorokhodov, Anatoly V and Gavrik, Maxim M and Mkrtchan, Nona N and Majdan, Marek and Valkovic, Peter and Rabarova, Daria and Barker-Collo, Suzanne and Jones, Kelly and Feigin, Valery L},
title = {A double-blind, placebo-controlled, randomized, multi-centre, phase III study of MLC901 (NeuroAiDTMII) for the treatment of cognitive impairment after mild traumatic brain injury},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0310229}
}
EUVIMED